Compared with people starting topiramate, those starting GLP-1 drugs were 48% less likely to start valproate, 42% less likely to start calcitonin gene-related peptide (CGRP) monoclonal antibodies, 35% less likely to start tricyclic antidepressants, and 23% less likely to start the class of drugs called gepants
Forty male albino rats (150 10 g) were randomly divided into four groups ( n = 10)
Chen Q, Shan D, Xie Y, et al
Conclusion Mazdutide and tirzepatide represent significant advancements in obesity and type 2 diabetes management, leveraging GLP-1-based mechanisms to achieve weight loss and glycaemic control
In studies of people with obesity who do not have Type 2 diabetes, tirzepatide helped them lose more than 20% of their body weight on average
Understanding your genetic peptide profile helps your PlexusDx provider customize your dose escalation, medication choice (semaglutide vs